A Study to Assess the Pharmacokinetics (PK) and Safety of Staccato Alprazolam in Adolescent Study Participants With Epilepsy

ClinicalTrials.gov ID: NCT04857307

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT04857307. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:10 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Open-Label Study to Evaluate the Pharmacokinetics, Tolerability, and Safety of a Single Dose of Staccato Alprazolam in Adolescent Study Participants With Epilepsy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of the study is to assess the pharmacokinetics (PK), tolerability, and safety of Staccato alprazolam in adolescent study participants with epilepsy following single-dose administration.

Study identification

NCT ID: NCT04857307
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: UCB Biopharma SRL; Industry
Enrollment: 14 participants

Conditions and interventions

Conditions

Epilepsy

Interventions

Alprazolam Drug

Drug

Eligibility (public fields only)

Age range: 12 Years to 17 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 28, 2021 (Actual)
Primary completion: Apr 5, 2022 (Actual)
Completion: Apr 5, 2022 (Actual)
Last update posted: Jun 30, 2022

2021 – 2022

United States locations

U.S. sites: 8
U.S. states: 8
U.S. cities: 8

Facility	City	State	ZIP	Site status
Up0100 102	Little Rock	Arkansas	72205	—
Up0100 110	Orlando	Florida	32806	—
Up0100 103	Honolulu	Hawaii	96817	—
Up0100 101	Bethesda	Maryland	20817	—
Up0100 108	Rochester	New York	14642	—
Up0100 106	Cincinnati	Ohio	45229	—
Up0100 105	Memphis	Tennessee	38103	—
Up0100 107	Tacoma	Washington	98405	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04857307, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 30, 2022 · Synced Nov 14, 2026